In this issue:
Sacituzumab tirumotecan in advanced NSCLC ± EGFR mutations
First-line maintenance lurbinectedin + atezolizumab in extensive-stage SCLC
Treatments and outcomes of EGFR-mutated NSCLC that transitioned to SCLC
Consolidation nivolumab ± ipilimumab after chemo-RT for unresectable stage IIIA–IIIB NSCLC
5-year survival with atezolizumab after chemotherapy in resected stage IB–IIIA NSCLC
Platinum-etoposide + durvalumab for extensive-stage SCLC with brain metastases
First-line lorlatinib vs. crizotinib in Asian patients with advanced ALK-positive NSCLC
KRASG12D vs. KRASG12C and EGFR-mutated lung adenocarcinomas
Please login below to download this issue (PDF)